MAP2K7 and myeloid leukemia: Since we could not detect the observed resistance pattern when cells were treated with other compounds, we hypothesize that, if at all, replication/proliferation differences selectively play a role in altering sensitivity to MEK inhibitors, perhaps by cell cycle-dependent differences in MEK/ERK activation, which has been reported for myeloid leukemia cell lines [43].